A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Description
Phase I
The maximum tolerated dose (MTD) will be determined in the phase I section of the trial.
Patients who fulfill eligibility criteria will be entered into the trial to GO-203-2c.
After the screening procedures confirm participation in the research study. The investigators are looking for the highest dose of the combination of study drugs that can be administered safely without severe or unmanageable side effects in participants that have acute myeloid leukemia (AML) not everyone who participates in this research study will receive the same dose of the study drug. The dose given will depend on the number of participants who have been enrolled in the study prior and how well the dose was tolerated.
A subsequent dose escalation will evaluate the combination of GO-203-2c and decitabine.
Phase II
The primary goal is to determine if the combination of the two drugs results in clinical response
